clinical trial · NCT06220864
SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.·phase1·recruiting·n = 400
Advanced Solid TumorSNV1521DB-1310AbirateroneDarolutamide
brief summary
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
started
Feb 23, 2024
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Apr 14, 2026
official title
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol